Skip to main content
. Author manuscript; available in PMC: 2021 Apr 28.
Published in final edited form as: Sci Transl Med. 2020 Oct 28;12(567):eaax4905. doi: 10.1126/scitranslmed.aax4905

Fig. 2. Construction of clinically relevant lead strain Sb-ABAB.

Fig. 2.

(A) Phenotype of the S. boulardii uracil auxotroph on MSM containing uracil and YPD media containing G418. (B) ABAB antibody in Sb-ABAB culture supernatant detected by Western blotting. (C) Toxin-neutralizing activity of Sb-ABAB culture supernatant compared with purified Fc-ABAB. (D) In vitro growth of Sb, Sb-EP, and Sb-ABAB. (E) ABAB expression in Sb-ABAB culture supernatants over multiple passages. (F) Persistence of Sb, Sb-EP, and Sb-ABAB in antibiotic cocktail–treated mice. (G) ABAB expression in Sb-ABAB culture supernatants over multiple passages in vitro for yeast recovered from fecal (f) samples in (F) versus nonpassaged strains from frozen master stocks. (H) Neutralizing activity of intestinal lavages from mice treated with Sb-EP and Sb-ABAB. (I) ABAB expression in feces from mice treated with Sb-EP and Sb-ABAB. **P < 0.01. Experimental data from in vivo studies represent one of at least three separate experiments with n = 3 mice per group and are presented as means ± SEM.